(Press-News.org) A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. The TACTOPS trial, which investigated the safety and clinical effects of autologous T cell therapy targeting multiple tumor antigens, was a collaboration between researchers at Baylor College of Medicine, the Dan L Duncan Comprehensive Cancer Center, the Center for Cell and Gene Therapy, Texas Children’s Hospital and Houston Methodist Hospital.
“We wanted to develop a targeted therapeutic that would hone the immune system on tumor-associated antigens (TAAs) that were present on malignant cells. We targeted five different antigens to deal with the polyclonal nature of the disease,” said co-corresponding author Dr. Ann Leen, professor of pediatrics – hematology and oncology in the Center for Cell and Gene Therapy.
“Pancreatic cancer doesn’t look as foreign to the immune system as other cancers do. This novel immunotherapy may help the immune system recognize and attack cancer cells in a way that other immunotherapies have not been able to do thus far,” said co-corresponding author Dr. Benjamin Musher, professor of medicine at Baylor and medical director of medical oncology at the Dan L Duncan Comprehensive Cancer Center.
Patients with pancreatic cancer were enrolled into one of three trial cohorts. Arm A included patients with advanced disease responding to first-line chemotherapy. Arm B included patients with metastatic disease who had progressed on first-line chemotherapy. Arm C included patients with surgically resectable disease. Each patient provided a blood sample, and individualized T cell therapy was manufactured at the Center for Cell and Gene Therapy. In total, 37 study participants received six monthly infusions of T cells.
Patients in arms A and C showed promising results, with 84.6% disease control rate in the group of patients responding to frontline chemotherapy (Arm A). Two out of nine patients in the those who underwent surgical resection (Arm C) remained disease-free more than five years after surgery. Researchers observed only 25% disease control in patients with refractory disease (Arm B). The therapy was extremely well-tolerated, with only one possibly treatment-related serious adverse side effect documented over all three cohorts.
Positive clinical outcomes correlated with functional T cell expansion and infused cell persistence in blood specimens collected during therapy compared to those collected at baseline. The investigators already are using the data from this study to refine their approach in preparation for the next trial, which may include T cell therapy alone or combined with other immune therapies.
“Nationwide, only 5% of pancreatic cancer patients enroll in clinical trials,” Musher said. “To improve pancreatic cancer outcomes meaningfully, we must explore all possible treatment options and enroll more patients in clinical trials. Studies like ours, which include robust correlative science, help us learn from successes and failures and facilitate further advances. They also provide patients with much-needed hope while helping them feel part of something larger than themselves.”
“The clinical and translational science expertise at Baylor within the Duncan Cancer Center and the Center for Cell and Gene Therapy enables our team to conduct complex trials that reach patients at different disease stages,” Leen said. “We could not accomplish this without strong collaboration between the lab and clinic, the excellent work of our regulatory team and top tier good manufacturing practices (GMP) facility.”
Drs. Spyridoula Vasileiou and Brandon G. Smaglo are co-first authors of this work with Musher. Other contributors include Catherine S. Robertson, Mengfen Wu, Tao Wang, Ayumi Watanabe, Manik Kuvalekar, Yovana Velazquez, Shamika Ketkar, Tamadar Al Doheyan, Penelope G. Papayanni, Aakash Shah, Natalia Lapteva, Bambi J. Grilley, George Van Buren, Premal D. Lulla, Helen E. Heslop, Cliona M. Rooney and Malcolm K. Brenner. All authors were affiliated with Baylor College of Medicine, the Center for Cell and Gene Therapy, Dan L Duncan Comprehensive Cancer Center, Texas Children’s Hospital and/or Houston Methodist Hospital when the study was conducted. See the publication for a full list of funding sources.
###
END
Autologous T cell therapy targeting multiple antigens shows promise treating pancreatic cancer
2026-01-13
ELSE PRESS RELEASES FROM THIS DATE:
First extensive study into marsupial gut microbiomes reveals new microbial species and antimicrobial resistance
2026-01-13
Marsupials are a group of mammals that encompass many of Australia's most iconic animals, unique because of their geographically isolated evolution. Despite their household names, their microbiomes remain under-researched.
"Understanding marsupial gut microbiomes advances our knowledge of host-microbiome evolution, helps explain adaptations to challenging diets like eucalyptus, and supports conservation efforts for threatened species through improved health management,” says Kate Bowerman, a microbiologist at the University of Queensland (UQ) and co-author ...
Study debunks myth of native Hawaiians causing bird extinctions
2026-01-13
Challenging a 50-year-old narrative about Hawaiʻi’s native birds, a new study from the University of Hawaiʻi at Mānoa found no scientific evidence that Indigenous People hunted waterbird species to extinction. Published in the journal Ecosphere, the research debunks this long-held myth and offers a new, integrated theory to explain the disappearances.
Researchers found no evidence that Indigenous People over-hunted birds to extinction. Instead, the authors suggest a new theory: the birds died out because of a combination of climate change, invasive species,and changes in how the land was used—most of which happened either prior to Polynesian ...
Tailored biochar could transform how crops grow, resist disease, and clean polluted soils
2026-01-13
Biochar has long been promoted as a climate-friendly soil amendment, but new research suggests that treating it as a one-size-fits-all solution may be limiting its full potential. A new open-access review published in Biochar shows that engineered biochar works best when it is carefully customized for specific agricultural and environmental goals, from boosting crop yields to suppressing soil-borne diseases and remediating contaminated land.
The international research team reviewed more than a decade of studies on engineered biochar and its interactions in the rhizosphere, the thin zone of soil surrounding ...
Biochar-based enzyme technology offers new path for cleaner water and soil
2026-01-13
A growing body of research suggests that combining enzymes with biochar, a carbon-rich material made from agricultural and organic waste, could transform how scientists clean polluted water and soil. A new review published in Biochar provides the most comprehensive overview to date of how biochar-immobilized enzymes work, why they are effective, and what challenges remain before the technology can be widely applied.
Environmental pollution from industrial chemicals, dyes, pharmaceuticals, antibiotics, and heavy metals continues to threaten ecosystems and human health worldwide. Traditional treatment methods often rely on energy-intensive processes or chemical reagents that can ...
Biochar helps farmland soils withstand extreme rain and drought by steadying carbon loss
2026-01-13
Researchers led by Yue Pan at Shenyang Agricultural University tested how swings between wet and dry conditions affect soil organic carbon breakdown in a clay loam Alfisol from Northeast China, and whether biochar can soften these impacts. The team incubated soils for 90 days under three moisture patterns and three levels of corn straw biochar to mimic the more extreme rainfall expected under climate change.
The study showed that stronger moisture variability sped up soil organic carbon decomposition, increasing cumulative carbon dioxide release by up to 17.2 percent compared with constant moisture. At the same time, fluctuating moisture boosted soil microbial activity and shifted the ...
New study reveals major gaps in global forest maps
2026-01-13
For decades, global efforts to combat climate change and protect biodiversity have relied on a high-tech promise: that satellite-derived maps can tell us exactly where the world's forests are.
But a new study from the University of Notre Dame reveals that these digital baselines are often in sharp disagreement, creating confusion that threatens to undermine effective climate funding and international development efforts. Because these maps determine everything from carbon storage estimates to the enactment of conservation policies, even small discrepancies can have serious ...
Ochsner Health names Dr. Timothy Riddell executive vice president and chief operating officer
2026-01-13
NEW ORLEANS – Jan. 13, 2026 – Ochsner Health has appointed Dr. Timothy Riddell as its new executive vice president and chief operating officer. In this role, Dr. Riddell will oversee clinical operations across the system’s 47 hospitals and more than 370 health and urgent care centers. He plays a vital part in guiding Ochsner toward its long-term goals for sustainability and success.
Dr. Riddell brings 28 years of experience within the Ochsner group practice to his new position. He began his career with the health system as a family medicine resident in 1997. A Louisiana native, Dr. Riddell has spent decades caring for families across ...
Can future-focused thoughts help smokers quit?
2026-01-13
As the warning label on every pack of cigarettes tells us, smoking is harmful. It’s the leading preventable cause of death, disease and disability.
And yet, nearly 15 percent of adults in the United States still smoke.
“Most indicate they want to quit,” said Jeff Stein, an addiction researcher and assistant professor with Virginia Tech’s Fralin Biomedical Research Institute at VTC. “But knowing that smoking affects your health isn’t enough to motivate people. The future is just too abstract and often doesn’t feel real.”
If ...
From brain scans to alloys: Teaching AI to make sense of complex research data
2026-01-13
UNIVERSITY PARK, Pa. — Artificial intelligence (AI) is increasingly used to analyze medical images, materials data and scientific measurements, but many systems struggle when real-world data do not match ideal conditions. Measurements collected from different instruments, experiments or simulations often vary widely in resolution, noise and reliability. Traditional machine-learning models typically assume those differences are negligible — an assumption that can limit accuracy and trustworthiness.
To address this issue, Penn State researchers have developed a new artificial intelligence framework with potential implications for fields ranging from Alzheimer’s disease ...
Stem Cell Reports seeks early career editors to join the editorial board
2026-01-13
Stem Cell Reports, the peer-reviewed, open-access journal of the International Society for Stem Cell Research (ISSCR), today announced a call for applications to serve on its editorial team as an Early Career Editor, a prestigious opportunity for outstanding, early-career scientists to help shape the future of stem cell publishing. The deadline to apply is 13 March 2026.
“Publishing in Stem Cell Reports and serving as an early career editor has given me unique insights into studies outside my immediate field, while reinforcing my commitment ...